SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on May 22, 2023, covering events occurring on May 16, 2023. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The filing details a private placement transaction and the issuance of unregistered equity securities.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) as it is a current report regarding a specific event. However, it discloses the following capital raise metrics:
- Total Consideration Raised: $2,500,747.51
- Common Shares Sold: 1,798,452 shares
- Share Purchase Price: $1.3905 per share
- Warrants Issued: Warrants to purchase 899,226 shares (50% of shares sold)
- Warrant Exercise Price: $1.328 per share
- Warrant Terms: Exercisable after six months; expire five and one-half years from issuance.
Material Changes and Unregistered Sales
In addition to the primary private placement, the company issued a warrant to Laidlaw & Company (UK) Ltd. as compensation for services under an engagement agreement dated February 24, 2023.
- Laidlaw Warrant Details: Right to purchase 62,698 shares at $1.328 per share.
- Laidlaw Warrant Terms: Exercisable after six months; expire five and one-half years from issuance.
- Regulatory Basis: Both the primary offering and the Laidlaw warrant were sold in reliance on exemptions from registration under Section 4(a)(2) and Regulation D of the Securities Act of 1933.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard representations and warranties typical for such transactions. The company notes that the summaries of the Purchase Agreement and Warrants are qualified by reference to the full text of the exhibits attached to the report.
Investor Verification Checklist
- Verify the dilution impact of the 1,798,452 new shares and the potential 899,226 warrant shares on existing shareholders.
- Confirm the identity of the institutional and accredited investors participating in the May PIPE.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions on the company.
- Assess the company's cash runway post-transaction, noting the filing does not disclose current cash balances or burn rates.
- Monitor the exercise of the Laidlaw warrant and any future compensation-related equity issuances.